Moderna Surges 13.76% as Cell Therapy Reveal and FDA Momentum Ignite MRNA.US

MRNA.US Explodes Higher, Tops the Index

Moderna shares surged 13.76% on June 26, 2026, adding $8.21 to reach $67.88 — a move that placed the stock at the front of the broader equity market. The single-session gain extends an already aggressive run: over the past month, the stock has climbed 44.43%, swinging between a low of $43.86 and a high of $69.23. The six-month picture is even more striking, with a gain of 119.68% off a low of $29.02. Over the trailing twelve months, MRNA.US has advanced 151.54%, with a 52-week low of $22.24 and a 52-week high of $67.58.

Cell Therapy Reveal and FDA Backing Drive the Breakout

Analysis suggests today's move was driven by two converging catalysts. First, Moderna unveiled a new cell therapy program at its Science Day event, with the company highlighting the expanding potential of its mRNA platform across multiple modalities. According to finance.yahoo.com, the Science Day provided a broad overview of research and early development programs, including validation of a T-cell engager modality with mRNA-2808 in multiple myeloma, supporting rapid advancement of a second T-cell engager, mRNA-2151, in ovarian cancer. The company also introduced an in vivo CAR-T modality with mRNA-6007 moving into early development for autoimmune diseases. Market drivers include the company's stated strategic direction toward becoming a diversified, multi-modality biotechnology company managing multiple commercial franchises. Second, investor confidence was reinforced by recent unanimous FDA advisory panel support for mFlusiva, Moderna's mRNA-based flu shot. Finance.yahoo.com reported that the FDA's Vaccines and Related Biological Products Advisory Committee unanimously backed mFlusiva for adults 50 and older, after phase 3 data showed it to be about 27% more effective than a standard flu vaccine. Analysis suggests this endorsement positions the mRNA platform for a potential second major commercial use beyond COVID-19. Fool.com noted the stock has already doubled this year and is still racing toward a major catalyst.

Historical Highs in Sight as Momentum Builds

The one-month high of $69.23 represents the nearest overhead reference point visible in the historical data. On the downside, the one-month low of $43.86 and the six-month low of $29.02 mark the range from which the current rally has been constructed. The 151.54% gain over the trailing twelve months, off a low of $22.24, underscores the scale of the recovery. The pipeline of upcoming regulatory and clinical milestones — including the potential commercial trajectory of mFlusiva and the early-stage cell therapy programs — represents the next set of fundamental inflection points that analysis suggests the market will be watching closely.